Inhibition of EZH2 exerts antitumorigenic effects in renal cell carcinoma via LATS1
暂无分享,去创建一个
Sung-Yul Park | Y. Yoon | S. Hong | H. Hwang | Da Hyeon Son | Eun Song Kim
[1] S. Zhuang,et al. Histone Methyltransferase EZH2: A Potential Therapeutic Target for Kidney Diseases , 2021, Frontiers in Physiology.
[2] A. Jemal,et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.
[3] K. Maedler,et al. Hippo Signaling: Key Emerging Pathway in Cellular and Whole-Body Metabolism , 2018, Trends in Endocrinology & Metabolism.
[4] R. Uzzo,et al. Resistance to Systemic Therapies in Clear Cell Renal Cell Carcinoma: Mechanisms and Management Strategies , 2018, Molecular Cancer Therapeutics.
[5] W. Béguelin,et al. Enhancer of zeste homolog 2 (EZH2) inhibitors , 2018, Leukemia & lymphoma.
[6] J. Bai,et al. EZH2 promotes hepatocellular carcinoma progression through modulating miR-22/galectin-9 axis , 2018, Journal of experimental & clinical cancer research : CR.
[7] Peter C. Hollenhorst,et al. EZH2 Modifies Sunitinib Resistance in Renal Cell Carcinoma by Kinome Reprogramming. , 2017, Cancer research.
[8] S. Welford,et al. HIF drives lipid deposition and cancer in ccRCC via repression of fatty acid metabolism , 2017, Nature Communications.
[9] Lisa C. Wallace,et al. Targeting Glioma Stem Cells through Combined BMI1 and EZH2 Inhibition , 2017, Nature Medicine.
[10] J. Minna,et al. Developing EZH2-Targeted Therapy for Lung Cancer. , 2016, Cancer discovery.
[11] R. Margueron,et al. Association between EZH2 expression, silencing of tumor suppressors and disease outcome in solid tumors , 2016, Cell cycle.
[12] S. Zhuang,et al. Enhancer of Zeste Homolog 2 Inhibition Attenuates Renal Fibrosis by Maintaining Smad7 and Phosphatase and Tensin Homolog Expression. , 2016, Journal of the American Society of Nephrology : JASN.
[13] C. Roberts,et al. Targeting EZH2 in cancer , 2016, Nature Medicine.
[14] Steven J. M. Jones,et al. Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. , 2016, The New England journal of medicine.
[15] Hongqing Zhao,et al. Prognostic Significance of EZH2 Expression in Non-Small Cell Lung Cancer: A Meta-analysis , 2016, Scientific Reports.
[16] Kun-Liang Guan,et al. Mechanisms of Hippo pathway regulation , 2016, Genes & development.
[17] S. Bicciato,et al. Aerobic glycolysis tunes YAP/TAZ transcriptional activity , 2015, The EMBO journal.
[18] K. Guan,et al. Cellular energy stress induces AMPK-mediated regulation of YAP and the Hippo pathway , 2015, Nature Cell Biology.
[19] Randy L. Johnson,et al. AMPK modulates Hippo pathway activity to regulate energy homeostasis , 2015, Nature Cell Biology.
[20] J. Asara,et al. Energy stress regulates hippo-YAP signaling involving AMPK-mediated regulation of angiomotin-like 1 protein. , 2014, Cell reports.
[21] Lawrence A. Donehower,et al. The somatic genomic landscape of chromophobe renal cell carcinoma. , 2014, Cancer cell.
[22] M. Hung,et al. Regulation and Role of EZH2 in Cancer , 2014, Cancer research and treatment : official journal of Korean Cancer Association.
[23] K. Guan,et al. The Hippo signaling pathway in stem cell biology and cancer , 2014, EMBO reports.
[24] C. Morais. Sunitinib resistance in renal cell carcinoma , 2014, Journal of kidney cancer and VHL.
[25] Tim J. Wigle,et al. Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2-Mutant Non-Hodgkin Lymphoma , 2014, Molecular Cancer Therapeutics.
[26] The Cancer Genome Atlas Research Network. COMPREHENSIVE MOLECULAR CHARACTERIZATION OF CLEAR CELL RENAL CELL CARCINOMA , 2013, Nature.
[27] H. Moch. An overview of renal cell cancer: pathology and genetics. , 2013, Seminars in cancer biology.
[28] Claudio R. Santos,et al. Lipid metabolism in cancer , 2012, The FEBS journal.
[29] Kevin W Eliceiri,et al. NIH Image to ImageJ: 25 years of image analysis , 2012, Nature Methods.
[30] R. Mehra,et al. Polycomb protein EZH2 regulates tumor invasion via the transcriptional repression of the metastasis suppressor RKIP in breast and prostate cancer. , 2012, Cancer research.
[31] Lothar Hennighausen,et al. EZH2 Methyltransferase and H3K27 Methylation in Breast Cancer , 2011, International journal of biological sciences.
[32] S. Goldberg,et al. Renal Cancer Resistance to Antiangiogenic Therapy Is Delayed by Restoration of Angiostatic Signaling , 2010, Molecular Cancer Therapeutics.
[33] Mala Sinha,et al. Pathway Signature and Cellular Differentiation in Clear Cell Renal Cell Carcinoma , 2010, PloS one.
[34] M. Fraga,et al. The Polycomb group protein EZH2 directly controls DNA methylation , 2007, Nature.
[35] T. Roskams,et al. Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer: a review. , 2006, Annals of Oncology.
[36] N. Palavan-Unsal,et al. Increased Expression of EZH2, a Polycomb Group Protein, in Bladder Carcinoma , 2005, Urologia Internationalis.
[37] Hengbin Wang,et al. Role of Histone H3 Lysine 27 Methylation in Polycomb-Group Silencing , 2002, Science.
[38] J. Mesirov,et al. The Molecular Signatures Database (MSigDB) hallmark gene set collection. , 2015, Cell systems.